Pfizer Price to Book Ratio 2012-2026 | PFE
Historical price to book ratio values for Pfizer (PFE) over the last 10 years. The current price to book ratio for Pfizer as of September 04, 2026 is 1.90.
| Pfizer Price/Book Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | Book Value per Share | Price to Book Ratio |
| 2026-09-04 | 28.45 | 1.90 | |
| 2026-06-30 | 23.67 | $15.00 | 1.58 |
| 2026-03-31 | 27.15 | $15.86 | 1.71 |
| 2025-12-31 | 23.68 | $15.26 | 1.55 |
| 2025-09-30 | 23.81 | $16.37 | 1.45 |
| 2025-06-30 | 22.27 | $15.66 | 1.42 |
| 2025-03-31 | 22.84 | $15.94 | 1.43 |
| 2024-12-31 | 23.53 | $15.62 | 1.51 |
| 2024-09-30 | 25.27 | $16.34 | 1.55 |
| 2024-06-30 | 24.09 | $15.52 | 1.55 |
| 2024-03-31 | 23.54 | $16.33 | 1.44 |
| 2023-12-31 | 24.06 | $15.81 | 1.52 |
| 2023-09-30 | 27.35 | $17.22 | 1.59 |
| 2023-06-30 | 29.91 | $17.59 | 1.70 |
| 2023-03-31 | 32.92 | $17.93 | 1.84 |
| 2022-12-31 | 40.96 | $17.08 | 2.40 |
| 2022-09-30 | 34.68 | $16.55 | 2.10 |
| 2022-06-30 | 41.24 | $15.64 | 2.64 |
| 2022-03-31 | 40.39 | $14.79 | 2.73 |
| 2021-12-31 | 45.72 | $13.78 | 3.32 |
| 2021-09-30 | 33.01 | $13.54 | 2.44 |
| 2021-06-30 | 29.79 | $12.56 | 2.37 |
| 2021-03-31 | 27.29 | $12.31 | 2.22 |
| 2020-12-31 | 27.43 | $11.40 | 2.41 |
| 2020-09-30 | 25.68 | $11.79 | 2.18 |
| 2020-06-30 | 22.66 | $11.62 | 1.95 |
| 2020-03-31 | 22.40 | $11.77 | 1.90 |
| 2019-12-31 | 26.61 | $11.46 | 2.32 |
| 2019-09-30 | 24.17 | $11.82 | 2.04 |
| 2019-06-30 | 28.87 | $10.77 | 2.68 |
| 2019-03-31 | 28.06 | $10.65 | 2.63 |
| 2018-12-31 | 28.59 | $11.15 | 2.56 |
| 2018-09-30 | 28.64 | $12.40 | 2.31 |
| 2018-06-30 | 23.38 | $11.96 | 1.95 |
| 2018-03-31 | 22.65 | $12.06 | 1.88 |
| 2017-12-31 | 22.90 | $11.98 | 1.91 |
| 2017-09-30 | 22.37 | $10.25 | 2.18 |
| 2017-06-30 | 20.84 | $9.87 | 2.11 |
| 2017-03-31 | 21.02 | $9.84 | 2.14 |
| 2016-12-31 | 19.76 | $9.86 | 2.00 |
| 2016-09-30 | 20.40 | $10.48 | 1.95 |
| 2016-06-30 | 21.03 | $10.40 | 2.02 |
| 2016-03-31 | 17.55 | $10.44 | 1.68 |
| 2015-12-31 | 18.92 | $10.53 | 1.80 |
| 2015-09-30 | 18.26 | $10.87 | 1.68 |
| 2015-06-30 | 19.35 | $10.89 | 1.78 |
| 2015-03-31 | 19.91 | $10.98 | 1.81 |
| 2014-12-31 | 17.67 | $11.38 | 1.55 |
| 2014-09-30 | 16.63 | $12.43 | 1.34 |
| 2014-06-30 | 16.55 | $12.14 | 1.36 |
| 2014-03-31 | 17.75 | $12.24 | 1.45 |
| 2013-12-31 | 16.78 | $11.97 | 1.40 |
| 2013-09-30 | 15.62 | $12.09 | 1.29 |
| 2013-06-30 | 15.11 | $11.93 | 1.27 |
| 2013-03-31 | 15.44 | $11.68 | 1.32 |
| 2012-12-31 | 13.30 | $11.23 | 1.18 |
| 2012-09-30 | 13.06 | $11.15 | 1.17 |
| 2012-06-30 | 11.98 | $10.71 | 1.12 |
| 2012-03-31 | 11.68 | $11.17 | 1.05 |
| 2011-12-31 | 11.04 | $10.91 | 1.01 |
| 2011-09-30 | 8.93 | $11.78 | 0.76 |
| 2011-06-30 | 10.29 | $11.40 | 0.90 |
| 2011-03-31 | 10.05 | $11.46 | 0.88 |
| 2010-12-31 | 8.58 | $11.02 | 0.78 |
| 2010-09-30 | 8.32 | $10.99 | 0.76 |
| 2010-06-30 | 6.84 | $10.81 | 0.63 |
| 2010-03-31 | 8.14 | $11.17 | 0.73 |
| 2009-12-31 | 8.55 | $11.21 | 0.76 |
| 2009-09-30 | 7.70 | $8.21 | 0.94 |
| 2009-06-30 | 6.91 | $9.37 | 0.74 |
| 2009-03-31 | 6.21 | $8.96 | 0.69 |
| 2008-12-31 | 7.90 | $8.56 | 0.92 |
| 2008-09-30 | 8.08 | $9.99 | 0.81 |
| 2008-06-30 | 7.53 | $9.88 | 0.76 |
| 2008-03-31 | 8.88 | $9.97 | 0.89 |
| 2007-12-31 | 9.51 | $9.62 | 0.99 |
| 2007-09-30 | 10.10 | $9.75 | 1.04 |
| 2007-06-30 | 10.45 | $9.83 | 1.06 |
| 2007-03-31 | 10.21 | $10.33 | 0.99 |
| 2006-12-31 | 10.36 | $10.02 | 1.03 |
| 2006-09-30 | 11.24 | $9.67 | 1.16 |
| 2006-06-30 | 9.22 | $9.39 | 0.98 |
| 2006-03-31 | 9.69 | $9.50 | 1.02 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $162.156B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $1081.958B | 36.50 |
| Johnson & Johnson (JNJ) | United States | $663.276B | 25.34 |
| AbbVie (ABBV) | United States | $453.112B | 23.59 |
| Merck (MRK) | United States | $370.890B | 46.83 |
| Roche Holding AG (RHHBY) | Switzerland | $350.157B | 0.00 |
| Novartis AG (NVS) | Switzerland | $305.285B | 18.43 |
| Novo Nordisk (NVO) | Denmark | $208.069B | 11.59 |
| Sanofi (SNY) | France | $107.257B | 9.03 |
| Bayer (BAYRY) | Germany | $55.767B | 9.92 |
| Innoviva (INVA) | United States | $1.541B | 5.27 |